Taken together, we found that the ongoing monitoring of BCR-ABL1 transcripts using ddPCR was a reliable approach to monitor MRD of patients with Ph+ ALL who have absolute quantitation and great applicability. This evidence concerns the gene BCR and acute lymphoblastic leukemia.